NGEN — Nervgen Pharma Income Statement
0.000.00%
Last trade - 00:00
- CA$151.74m
- CA$137.18m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.36 | 9.86 | 11.2 | 12.8 | 23.5 |
Operating Profit | -1.36 | -9.86 | -11.2 | -12.8 | -23.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.36 | -9.77 | -11.2 | -12.7 | -20.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.36 | -9.77 | -11.2 | -12.7 | -20.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.36 | -9.77 | -11.2 | -12.7 | -20.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.36 | -9.77 | -11.2 | -12.7 | -20.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.05 | -0.377 | -0.348 | -0.324 | -0.394 |
Dividends per Share |